Wednesday, 14 November 2018 to Thursday, 15 November 2018
Poster
6

Development of predictive in vitro assays for cardiovascular toxicity using iPSC derived cardiomyocytes

Authors

W Stebbeds1; P Clements1; A Brown1; J Francis1
1 GlaxoSmithKline (GSK), UK

Abstract

Background: 27% of drugs fail to reach phase I due to cardiovascular liability. The use of human iPSc derived cardiomyocytes (CMCs) as a predictive model for cardiovascular toxicity has been become a promising avenue of research. The aim of this research is to develop predictive assays for cardiovascular toxicity using iPSC derived CMCs
Methods: iPSc derived CMCs were exposed to prototypic compounds and endogenous factors and the effect of these insults was assessed by both functional and structural endpoints.
Results: These cells accurately predicted the effects of the standard chronotropes used as well as accurately predicting the effect of the structural toxicants used. In its current format, the model was unable to capture any inotropic effects.
Conclusions: Multiparametric assays using iPSc derived CMCs show promise in predicting both structural and chronotropic effects of putative drugs, however further work is needed to predict inotropy

Schedule

Hosted By

ELRIG

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis